Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 6/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1708187 | 1.00 | ALOX5 (0.58) | ALOX5CA1CA2ALDH1A1PKM | |
| SCHEMBL1285898 | 1.00 | ALOX5 (0.58) | ALOX5CA1CA2ALDH1A1PKM | |
| SCHEMBL3057546 | 0.83 | ALOX5 (0.58) | ALOX5ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL3069141 | 0.83 | ALOX5 (0.58) | ALOX5ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL3057548 | 0.83 | ALOX5 (0.58) | ALOX5ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL3486156 | 0.82 | ALDH1A1 (0.48) | ALOX5ALDH1A1PKMMEN1KMT2A | |
| SCHEMBL28868955 | 0.80 | ALDH1A1 (0.61) | ALDH1A1MEN1KMT2AHTTMAPT | |
| SCHEMBL453158 | 0.80 | ALOX5 (0.55) | ALOX5ALDH1A1PKMMEN1KMT2A | |
| SCHEMBL350063 | 0.80 | ITGB3 (0.62) | ALOX5ALDH1A1PKMMEN1KMT2A | |
| SCHEMBL453156 | 0.80 | ALOX5 (0.55) | ALOX5ALDH1A1PKMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| US-12441745-B2 | Processes and compounds | RADIUS PHARMACEUTICALS, INC. (US) | 2025-10-14 | — | — | US | claimed |
| CN-119569588-A | Preparation method and intermediate of ilast hydrochloride | 杭州诺澳生物医药科技有限公司 | 2025-03-07 | — | — | CN | claimed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | claimed |
| US-20230192685-A1 | METHOD FOR PRODUCING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-22 | — | — | US | claimed |
| EP-4163280-A1 | METHOD FOR PRODUCING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2023-04-12 | — | — | EP | claimed |
| EP-3924328-A1 | PROCESSES AND COMPOUNDS | Radius Pharmaceuticals, Inc. (US) | 2021-12-22 | — | — | EP | claimed |
| WO-2021241611-A1 | METHOD FOR PRODUCING HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 | 2021-12-02 | — | — | WO | claimed |
| WO-2020167855-A1 | PROCESSES AND COMPOUNDS | RADIUS PHARMACEUTICALS, INC. (US) | 2020-08-20 | — | — | WO | claimed |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-09-11 | — | — | US | claimed |
| US-20110152543-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE (S)-(-)-2-(N-PROPYLAMINO)-5-METHOXYTETRALINE AND (S)-(-)-2-(N-PROPYLAMINO)-5-HYDROXYTETRALINE COMPOUNDS | INTERQUIM, S.A. (ES) | 2011-06-23 | — | — | US | claimed |
| WO-2010118241-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2010-10-14 | — | — | WO | claimed |
| WO-2010043571-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE (S)-(-)-2-(N-PROPYLAMINO)-5-METHOXYTETRALINE AND (S)-(-)-2-(N-PROPYLAMINO)-5-HYDROXYTETRALINE COMPOUNDS | INTERQUIM, S.A. (ES) | 2010-04-22 | — | — | WO | claimed |
| EP-1346988-B1 | PROCESS FOR PREPARING OPTICALLY ACTIVE 2,3-DIHYDRO- BENZOFURAN COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2008-11-12 | — | — | EP | claimed |
| US-7105698-B2 | Process for the separation of R(-)-and S(+)-5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2- methoxybenzenesulfonamide | RAGACTIVES, S.L. (ES) | 2006-09-12 | — | — | US | claimed |
| EP-1522538-A2 | METHOD OF SEPARATING R(-)- AND S(+)-5- 2- 2-(2-ETHOXYPHENOXY)ETHYL]AMINO]PROPYL-2-METHOXYBENZENE-SULPHONAMIDE | Ragactives, S.L. (ES) | 2005-04-13 | — | — | EP | claimed |
| US-6878831-B2 | Process for preparing optically active 2,3-dihydrobenzofuran compounds | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-04-12 | — | — | US | claimed |
| US-20050004398-A1 | Process for the separation of R(-)-and S(+)-5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzenesulfonamide | RAGACTIVES, S.L. | 2005-01-06 | — | — | US | claimed |
| US-20040077712-A1 | Process for preparing optically active 2,3-dihydrobenzofuran compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-22 | — | — | US | claimed |
| EP-1346988-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE 2,3-DIHYDRO- BENZOFURAN COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2003-09-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | PTPRCAP, PTPRF, PTPRS | ALOX5 4159/4885CA1 4047/4885CA2 3509/4885 |
| US-12441745-B2 | Processes and compounds | ESR1, ESR2, CYP19A1 | ALOX5 2737/4885CA1 2504/4885CA2 4350/4885 |
| US-20040077712-A1 | Process for preparing optically active 2,3-dihydrobenzofuran compounds | ALDH1A2, PARK7, DHPS | ALOX5 873/4885CA1 1908/4885CA2 1878/4885 |
| US-20230192685-A1 | METHOD FOR PRODUCING HETEROCYCLIC COMPOUND | MALT1, CYP51A1, ME1 | ALOX5 759/4885CA1 187/4885CA2 114/4885 |
| US-20110152543-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE (S)-(-)-2-(N-PROPYLAMINO)-5-METHOXYTETRALINE AND (S)-(-)-2-(N-PROPYLAMINO)-5-HYDROXYTETRALINE COMPOUNDS | PARK7, THOP1, SNCA | ALOX5 372/4885CA1 4506/4885CA2 3415/4885 |
| US-20050004398-A1 | Process for the separation of R(-)-and S(+)-5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzenesulfonamide | ADRB2, ADRB1, ADRA2B | ALOX5 1800/4885CA1 2978/4885CA2 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.